株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

マンノース-6-リン酸イソメラーゼ(MPI)欠損症 - 市場洞察、疫学、予測 2028年

Mannose Phosphate Isomerase (MPI) Deficiency - Market Insights, Epidemiology and Market Forecast - 2028

発行 DelveInsight Business Research LLP 商品コード 911510
出版日 ページ情報 英文 66 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=109.62円で換算しております。
Back to Top
マンノース-6-リン酸イソメラーゼ(MPI)欠損症 - 市場洞察、疫学、予測 2028年 Mannose Phosphate Isomerase (MPI) Deficiency - Market Insights, Epidemiology and Market Forecast - 2028
出版日: 2019年09月01日 ページ情報: 英文 66 Pages
概要

主要6カ国(米国、英国、ドイツ、フランス、イタリア、スペイン)におけるマンノース-6-リン酸イソメラーゼ(MPI)欠損症の2016年の有病数は84人、その市場規模は61万米ドルと推計されています。

当レポートでは、主要6カ国(米国、英国、ドイツ、フランス、イタリア、スペイン)のマンノース-6-リン酸イソメラーゼ(MPI)欠損症市場を調査し、市場の概要、疾病の概要や新薬のプロファイル、全体および各国の市場動向、疫学的予測、市場規模、有病数の推移と予測、アンメットニーズ、市場の成長要因および障壁などをまとめています。

目次

第1章 重要洞察

第2章 市場概要

  • 分布状況(実績値)
  • 分布状況(予測値)

第3章 疾病背景と概要

  • イントロダクション
  • 概要
  • 病態生理
  • 原因
  • 症状
  • 診断

第4章 先天性糖鎖合成異常症 (CDG) の治療に取り組む組織

第5章 疫学と患者人口

  • 主な調査結果
  • キーオピニオンリーダーの見解
  • 主要6カ国の仮定と根拠

第6章 主要6カ国のマンノース-6-リン酸イソメラーゼ(MPI)欠損症の有病数

第7章 マンノース-6-リン酸イソメラーゼ(MPI)欠損症の疫学:国別

  • 米国
    • 総診断有病数
    • 有病数:臨床症状別
  • 欧州5カ国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • 英国

第8章 マンノース-6-リン酸イソメラーゼ(MPI)欠損症の治療と管理

第9章 アンメットニーズ

第10章 新薬

  • ORL-1M:Orpha Labs
    • 医薬品概要
    • 臨床開発
    • 臨床試験情報
    • 製品プロファイル

第11章 その他の有望な治療薬

  • CERC-802:Cerecor Inc.
    • 医薬品概要
    • その他の開発動向
    • 製品プロファイル

第12章 主要6カ国のマンノース-6-リン酸イソメラーゼ(MPI)欠損症市場の分析

  • 主な調査結果
  • キーオピニオンリーダーの意見:治療・診断
  • 主要6カ国市場の見通し
  • 主要6カ国の市場規模

第13章 市場見通し:国別

  • 米国の市場規模
    • 総市場規模
    • 市場規模:治療薬別

第14章 欧州5カ国の市場規模

  • ドイツの市場規模
    • 総市場規模
    • 市場規模:治療薬別
  • フランスの市場規模
    • 総市場規模
    • 市場規模:治療薬別
  • イタリアの市場規模
    • 総市場規模
    • 市場規模:治療薬別
  • スペインの市場規模
    • 総市場規模
    • 市場規模:治療薬別
  • 英国の市場規模
    • 総市場規模
    • 市場規模:治療薬別

第15章 市場の成長要因

第16章 市場の障壁

第17章 付録

  • 調査手法

第18章 DelveInsightのサービス内容

第19章 免責事項

第20章 DelveInsightについて

図表

List of Tables

Table 1 Prevalent Patient Population of MPI Deficiency in 6MM (2016-2028)

Table 2 Total Diagnosed Prevalent Cases of MPI Deficiency in the US (2016-2028)

Table 3 Prevalence of MPI Deficiency based on Clinical Manifestations in the US (2016-2028)

Table 4 Total Diagnosed Prevalent Cases of MPI Deficiency in Germany (2016-2028)

Table 5 Prevalence of MPI Deficiency based on Clinical Manifestations in Germany (2016-2028)

Table 6 Total Diagnosed Prevalent Cases of MPI Deficiency in France (2016-2028)

Table 7 Prevalence of MPI Deficiency based on Clinical Manifestations in France (2016-2028)

Table 8 Total Diagnosed Prevalent Cases of MPI Deficiency in Italy (2016-2028)

Table 9 Prevalence of MPI Deficiency based on Clinical Manifestations in Italy (2016-2028)

Table 10 Total Diagnosed Prevalent Cases of MPI Deficiency in Spain (2016-2028)

Table 11 Prevalence of MPI Deficiency based on Clinical Manifestations in Spain (2016-2028)

Table 12 Total Diagnosed Prevalent Cases of MPI Deficiency in The UK (2016-2028)

Table 13 Prevalence of MPI Deficiency based on Clinical Manifestations in The UK (2016-2028)

Table 14 ORL-1M - D-mannose Clinical Trial Description, 2019

Table 15 ORL-1M - Product Profile, 2019

Table 16 CERC-801 - Product Profile, 2019

Table 17 6 Major Market Size of MPI Deficiency in USD Million (2016-2028)

Table 18 The United States Market Size of MPI Deficiency in USD Million (2016-2028)

Table 19 The US Market Size of MPI Deficiency by Therapies in USD Million (2016-2028)

Table 20 Market Size of MPI Deficiency in Germany, USD Million (2016-2028)

Table 21 Germany Market Size of MPI Deficiency by Therapies in USD Million (2016-2028)

Table 22 France Market Size of MPI Deficiency in USD Million (2016-2028)

Table 23 France Market Size of MPI Deficiency by Therapies in USD Million (2016-2028)

Table 24 Italy Market Size of MPI Deficiency in USD Million (2016-2028)

Table 25 Italy Market Size of MPI Deficiency by Therapies in USD Million (2016-2028)

Table 26 Spain Market Size of MPI Deficiency in USD Million (2016-2028)

Table 27 Spain Market Size of MPI Deficiency by Therapies in USD Million (2016-2028)

Table 28 United Kingdom Market Size of MPI Deficiency in USD Million (2016-2028)

Table 29 UK Market Size of MPI Deficiency by Therapies in USD Million (2016-2028)

List of Figures

Figure 1 Schematic representation of Mannose Phosphate Isomerase (MPI) key role in glycolysis

Figure 2 Role of Mannose Phosphate Isomerase (MPI) in N-linked glycosylation

Figure 3 Lipid-linked oligosaccharide biosynthetic pathway

Figure 4 Associated Signs and Symptoms of MPI Deficiency

Figure 5 Prevalent Patient Population of MPI Deficiency in 6MM (2016-2028)

Figure 6 Total Diagnosed Prevalent Cases of MPI Deficiency in the US (2016-2028)

Figure 7 Prevalence of MPI Deficiency based on Clinical Manifestations in the US (2016-2028)

Figure 8 Total Diagnosed Prevalent Cases of MPI Deficiency in Germany (2016-2028)

Figure 9 Prevalence of MPI Deficiency based on Clinical Manifestations in Germany (2016-2028)

Figure 10 Total Diagnosed Prevalent Cases of MPI Deficiency in France (2016-2028)

Figure 11 Prevalence of MPI Deficiency based on Clinical Manifestations in France (2016-2028)

Figure 12 Total Diagnosed Prevalent Cases of MPI Deficiency in Italy (2016-2028)

Figure 13 Prevalence of MPI Deficiency based on Clinical Manifestations in Italy (2016-2028)

Figure 14 Total Diagnosed Prevalent Cases of MPI Deficiency in Spain (2016-2028)

Figure 15 Prevalence of MPI Deficiency based on Clinical Manifestations in Spain (2016-2028)

Figure 16 Total Diagnosed Prevalent Cases of MPI Deficiency in The UK (2016-2028)

Figure 17 Prevalence of MPI Deficiency based on Clinical Manifestations in The UK (2016-2028)

Figure 18 Unmet Needs of MPI deficiency

Figure 19 6 Major Market Size of MPI Deficiency in USD Million (2016-2028)

Figure 20 The United States Market Size of MPI Deficiency in USD Million (2016-2028)

Figure 21 The US Market Size of MPI Deficiency by Therapies in USD Million (2016-2028)

Figure 22 Market Size of MPI Deficiency in Germany, USD Million (2016-2028)

Figure 23 Germany Market Size of MPI Deficiency by Therapies in USD Million (2016-2028)

Figure 24 Market Size of MPI Deficiency in France USD Million (2016-2028)

Figure 25 France Market Size of MPI Deficiency by Therapies in USD Million (2016-2028)

Figure 26 Market Size of MPI Deficiency in Italy, USD Million (2016-2028)

Figure 27 Italy Market Size of MPI Deficiency by Therapies in USD Million (2016-2028)

Figure 28 Market Size of MPI Deficiency in Spain, USD Million (2016-2028)

Figure 29 Spain Market Size of MPI Deficiency by Therapies in USD Million (2016-2028)

Figure 30 Market Size of MPI Deficiency in the United Kingdom, USD Million (2016-2028)

Figure 31 The UK Market Size of MPI Deficiency by Therapies in USD Million (2016-2028)

Figure 32 Market Drivers of MPI Deficiency

Figure 33 Market Barriers of MPI deficiency

目次
Product Code: DIMI0676

DelveInsight's Mannose Phosphate Isomerase (MPI) Deficiency - Market Insights, Epidemiology and Market Forecast-2028' report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of MPI in the United States and EU5 (Germany, Spain, Italy, France and United Kingdom).

The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Mannose Phosphate Isomerase (MPI) deficiency from 2016 to 2028 segmented by six major markets. The Report also covers current treatment practice, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain and the United Kingdom)

Study Period: 2016-2028

Mannose Phosphate Isomerase (MPI) Deficiency - Disease Understanding and Treatment Algorithm

The DelveInsight Mannose Phosphate Isomerase (MPI) Deficiency market report gives the thorough understanding of the Mannose Phosphate Isomerase (MPI) Deficiency by including details such as disease definition, causes, symptoms, pathophysiology, and diagnostic trends. It also provides overview of treatment and management of the disease in the US and EU5.

Mannose Phosphate Isomerase (MPI) Deficiency Epidemiology

The Mannose Phosphate Isomerase (MPI) Deficiency epidemiology division provide the insights about historical and current patient pool and forecasted trend for every six major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and the prevalence based on clinical manifestations in the US and EU5.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (total diagnosed prevalent cases, and prevalence based on clinical manifestations) scenario of Mannose Phosphate Isomerase (MPI) Deficiency in the 6MM covering United States and EU5 countries (Germany, Spain, Italy, France and United Kingdom) from 2016-2028.

According to DelveInsight, total prevalent population of Mannose Phosphate Isomerase (MPI) Deficiency in six major markets was found to be 84 in 2016. 

Mannose Phosphate Isomerase (MPI) Deficiency Drug Chapters

This segment of the MPI Drug report encloses the detailed analysis of the emerging drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, and the latest news and press releases.

At present, therapeutic approach of MPI involves substrate replacement therapy i.e. the D-Mannose therapy. D-Mannose therapy has shown improvement in all major symptoms associated with the disease, but no benefits in liver conditions such as fibrosis and cirrhosis. Liver transplantation is the only resolution to control liver conditions associated with this disorder. Till date no drug has obtained approval for the treatment of MPI deficiency. Detailed chapter for upcoming therapies like ORL-1M (Orpha Labs), and other promising therapies such as CERC-802 (Cerecor Inc.) have been covered in the report.

Mannose Phosphate Isomerase (MPI) Deficiency Market Outlook

The MPI market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers.

This segment gives a through detail of emerging therapies and other promising therapies by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the market of Mannose Phosphate Isomerase (MPI) Deficiency in 6MM was found to be USD 0.61 Million in 2016.

Mannose Phosphate Isomerase (MPI) Deficiency Drugs Uptake

This section focusses on the rate of uptake of the potential drugs that will get launched in the market during the study period from 2016-2028. The analysis covers market uptake by drugs; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Mannose Phosphate Isomerase (MPI) Deficiency Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Pipeline Analysis
  • Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Mannose Phosphate Isomerase (MPI) Deficiency Report Key Strengths

  • 10 Year Forecast
  • 6MM Coverage
  • Epidemiology Segmentation
  • Drugs Uptake
  • Market Size by Therapies
  • Key Cross Competition

Mannose Phosphate Isomerase (MPI) Deficiency Report Assessment

  • Pipeline Product Profiles
  • Key Products and Key Players
  • Market Drivers and Barriers

Key Benefits

  • This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving Mannose Phosphate Isomerase (MPI) Deficiency market.
  • Organize sales and marketing efforts by identifying the best opportunities for Idiopathic Pulmonary Fibrosis market.
  • To understand the future market competition in the Mannose Phosphate Isomerase (MPI) Deficiency market.

Table of Contents

1. Key Insights

2. Mannose Phosphate Isomerase (MPI) Deficiency Market Overview at a Glance

  • 2.1 Market Share (%) Distribution of MPI Deficiency in 2016
  • 2.2 Market Share (%) Distribution of MPI Deficiency in 2028

3. Disease Background and Overview

  • 3.1 Introduction
  • 3.2 Facts about Mannose Phosphate Isomerase
  • 3.3 Pathophysiology
  • 3.4 Causes
  • 3.5 Symptoms
  • 3.6 Diagnosis

4. Organizations contributing toward CDG

5. Epidemiology and Patient Population

  • 5.1 Key Findings
  • 5.2 KOL's Views: Epidemiology
  • 5.3 Assumptions and Rationale 6MM

6. 6MM Total Prevalent Patient Population of MPI Deficiency

7. Country Wise-Epidemiology of MPI Deficiency

  • 7.1 The United States
    • 7.1.1 Total Diagnosed Prevalent Cases of MPI Deficiency in the United States
    • 7.1.2 Prevalence of MPI Deficiency based on Clinical Manifestations in the United States
  • 7.2 EU5
    • 7.2.1 Germany
      • 7.2.1.1 Total Diagnosed Prevalent Cases of MPI Deficiency in Germany
      • 7.2.1.2 Prevalence of MPI Deficiency based on Clinical Manifestations in Germany
    • 7.2.2 France
      • 7.2.2.1 Total Diagnosed Prevalent Cases of MPI Deficiency in France
      • 7.2.2.2 Prevalence of MPI Deficiency based on Clinical Manifestations in France
    • 7.2.3 Italy
      • 7.2.3.1 Total Diagnosed Prevalent Cases of MPI Deficiency in Italy
      • 7.2.3.2 Prevalence of MPI Deficiency based on Clinical Manifestations in Italy
    • 7.2.4 Spain
      • 7.2.4.1 Total Diagnosed Prevalent Cases of MPI Deficiency in Spain
      • 7.2.4.2 Prevalence of MPI Deficiency based on Clinical Manifestations in Spain
    • 7.2.5 The United Kingdom
      • 7.2.5.1 Total Diagnosed Prevalent Cases of MPI Deficiency in the UK
      • 7.2.5.2 Prevalence of MPI Deficiency based on Clinical Manifestations in The UK

8. Treatment and Management of MPI Deficiency

9. Unmet Needs

10. Emerging Therapies

  • 10.1 ORL-1M: Orpha Labs
    • 10.1.1 Drug Description
    • 10.1.2 Clinical Development
    • 10.1.3 Clinical Trials Information
    • 10.1.4 Product Profile

11. Other Promising Therapies

  • 11.1 CERC-802: Cerecor Inc.
    • 11.1.1 Drug Description
    • 11.1.2 Other Developmental Activities
    • 11.1.3 Product Profile

12. MPI Deficiency: 7 Major Market Analysis

  • 12.1 Key Findings
  • 12.2 KOL's Views: Treatment & Diagnosis
  • 12.3 Market Outlook 6MM
  • 12.4 Market Size of MPI Deficiency in 6MM

13. Market Outlook by Country

  • 13.1 United States Market Size
    • 13.1.1 Total Market Size of MPI Deficiency
    • 13.1.2 Market Size of MPI Deficiency by Therapies

14. EU-5 Countries: Market Outlook

  • 14.1 Germany
    • 14.1.1 Total Market size of MPI Deficiency
    • 14.1.2 Market Size of MPI Deficiency by Therapies
  • 14.2 France
    • 14.2.1 Total Market Size of MPI Deficiency
    • 14.2.2 Market Size of MPI Deficiency by Therapies
  • 14.3 Italy
    • 14.3.1 Total Market Size of MPI Deficiency
    • 14.3.2 Market Size of MPI Deficiency by Therapies
  • 14.4 Spain
    • 14.4.1 Total Market Size of MPI Deficiency
    • 14.4.2 Market Size of MPI Deficiency by Therapies
  • 14.5 United Kingdom
    • 14.5.1 Total Market Size of MPI Deficiency
    • 14.5.2 Market Size of MPI Deficiency by Therapies

15. Market Drivers

16. Market Barriers

17. Appendix

  • 17.1 Report Methodology

18. DelveInsight Capabilities

19. Disclaimer

20. About DelveInsight

Back to Top